Clinical trial · Interventional
Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival
Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival: a Randomized Controlled Trial
NCT07731425CI-TRIAL-00119515not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the survival benefits of new cancer drugs
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FDA explanation for progression-free survival (control) | Other | — | UNRESOLVED |
| FDA explanation for progression-free survival with overall survival data | Other | — | UNRESOLVED |
| NCI explanation for progression-free survival | Other | — | UNRESOLVED |
| NCI explanation for progression-free survival with overall survival data | Other | — | UNRESOLVED |
| Plain-language explanation of progression-free survival | Other | — | UNRESOLVED |
| Plain-language explanation of progression-free survival with overall survival data | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (6)
- type
- PLACEBO_COMPARATOR
- label
- FDA explanation for progression-free survival (control)
- interventionNames
- Other: FDA explanation for progression-free survival (control)
- type
- EXPERIMENTAL
- label
- FDA explanation for progression-free survival with overall survival data
- interventionNames
- Other: FDA explanation for progression-free survival with overall survival data
- type
- EXPERIMENTAL
- label
- NCI explanation for progression-free survival
- interventionNames
- Other: NCI explanation for progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * US adults with a current or former cancer diagnosis (excluding nonmelanoma skin cancer) * US adults 18 years of age and older, fluent in English, and residing in the United States. Exclusion Criteria: * Adults who do not have a former cancer diagnosis or who were diagnosed with nonmelanoma skin cancer; adults who complete the survey in under 150 seconds, and who do not meet the other inclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.